Li Zheqi, Seehawer Marco, Polyak Kornelia
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Nat Cell Biol. 2022 Aug;24(8):1192-1201. doi: 10.1038/s41556-022-00969-x. Epub 2022 Aug 8.
Intratumour heterogeneity (ITH) is a hallmark of cancer that drives tumour evolution and disease progression. Technological and computational advances have enabled us to assess ITH at unprecedented depths, yet this accumulating knowledge has not had a substantial clinical impact. This is in part due to a limited understanding of the functional relevance of ITH and the inadequacy of preclinical experimental models to reproduce it. Here, we discuss progress made in these areas and illuminate future directions.
肿瘤内异质性(ITH)是癌症的一个标志,它推动肿瘤进化和疾病进展。技术和计算方面的进步使我们能够以前所未有的深度评估ITH,但这些不断积累的知识尚未产生重大的临床影响。部分原因是对ITH功能相关性的理解有限,以及临床前实验模型不足以重现它。在这里,我们讨论这些领域取得的进展并阐明未来的方向。